{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T23:51:35Z","timestamp":1789429895181,"version":"build-2803163510"},"reference-count":54,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32202767"],"award-info":[{"award-number":["32202767"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["YZZY202402"],"award-info":[{"award-number":["YZZY202402"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Modern Agriculture Development Special Fund of Yangzhou, Jiangsu Province, China","award":["32202767"],"award-info":[{"award-number":["32202767"]}]},{"name":"Modern Agriculture Development Special Fund of Yangzhou, Jiangsu Province, China","award":["YZZY202402"],"award-info":[{"award-number":["YZZY202402"]}]},{"name":"Priority Academic Program Development of Jiangsu Higher Education Institutions","award":["32202767"],"award-info":[{"award-number":["32202767"]}]},{"name":"Priority Academic Program Development of Jiangsu Higher Education Institutions","award":["YZZY202402"],"award-info":[{"award-number":["YZZY202402"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>The ongoing global health crisis caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) necessitates the continuous development of innovative vaccine strategies, especially in light of emerging viral variants that could undermine the effectiveness of existing vaccines. In this study, we developed a recombinant virus-like particle (VLP) vaccine based on the Newcastle Disease Virus (NDV) platform, displaying a stabilized prefusion form of the SARS-CoV-2 spike (S) protein. This engineered S protein includes two proline substitutions (K986P, V987P) and a mutation at the cleavage site (RRAR to QQAQ), aimed at enhancing both its stability and immunogenicity. Using a prime-boost regimen, we administered NDV-VLP-S-3Q2P intramuscularly at different doses (2, 10, and 20 \u00b5g) to BALB\/c mice. Robust humoral responses were observed, with high titers of S-protein-specific IgG and neutralizing antibodies against SARS-CoV-2 pseudovirus, reaching titers of 1:2200\u20131:2560 post-boost. The vaccine also induced balanced Th1\/Th2 immune responses, evidenced by significant upregulation of cytokines (IFN-\u03b3, IL-2, and IL-4) and S-protein-specific IgG1 and IgG2a. Furthermore, strong activation of CD4+ and CD8+ T cells in the spleen and lungs confirmed the vaccine\u2019s ability to promote cellular immunity. These findings demonstrate that NDV-S3Q2P-VLP is a potent immunogen capable of eliciting robust humoral and cellular immune responses, highlighting its potential as a promising candidate for further clinical development in combating COVID-19.<\/jats:p>","DOI":"10.3390\/v16121932","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T03:40:56Z","timestamp":1734493256000},"page":"1932","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Development and Evaluation of a Newcastle Disease Virus-like Particle Vaccine Expressing SARS-CoV-2 Spike Protein with Protease-Resistant and Stability-Enhanced Modifications"],"prefix":"10.3390","volume":"16","author":[{"given":"Yu","family":"Chen","sequence":"first","affiliation":[{"name":"Animal Infectious Disease Laboratory, College of Veterinary Medicine, Yangzhou University, Yangzhou 225012, China"},{"name":"Jiangsu Co-Innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonosis, Yangzhou University, Yangzhou 225012, China"},{"name":"Jiangsu Key Laboratory of Zoonosis, Yangzhou University, Yangzhou 225012, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Tian","sequence":"additional","affiliation":[{"name":"Animal Infectious Disease Laboratory, College of Veterinary Medicine, Yangzhou University, Yangzhou 225012, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0615-1253","authenticated-orcid":false,"given":"Shunlin","family":"Hu","sequence":"additional","affiliation":[{"name":"Animal Infectious Disease Laboratory, College of Veterinary Medicine, Yangzhou University, Yangzhou 225012, China"},{"name":"Jiangsu Co-Innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonosis, Yangzhou University, Yangzhou 225012, China"},{"name":"Jiangsu Key Laboratory of Zoonosis, Yangzhou University, Yangzhou 225012, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9924-6646","authenticated-orcid":false,"given":"Xiufan","family":"Liu","sequence":"additional","affiliation":[{"name":"Animal Infectious Disease Laboratory, College of Veterinary Medicine, Yangzhou University, Yangzhou 225012, China"},{"name":"Jiangsu Co-Innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonosis, Yangzhou University, Yangzhou 225012, China"},{"name":"Jiangsu Key Laboratory of Zoonosis, Yangzhou University, Yangzhou 225012, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"102195","DOI":"10.1016\/j.arr.2024.102195","article-title":"The interference between SARS-COV-2 and Alzheimer\u2019s disease: Potential immunological and neurobiological crosstalk from a kinase perspective reveals a delayed pandemic","volume":"94","author":"Mansour","year":"2024","journal-title":"Ageing Res. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"947","DOI":"10.3201\/eid3005.230357","article-title":"COVID-19 Vaccination Site Accessibility, United States, December 11, 2020-March 29, 2022","volume":"30","author":"Yee","year":"2024","journal-title":"Emerg. Infect. Dis."},{"key":"ref_3","first-page":"162","article-title":"SARS-CoV-2 variant biology: Immune escape, transmission and fitness","volume":"21","author":"Carabelli","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.it.2020.10.004","article-title":"Mechanisms of SARS-CoV-2 Transmission and Pathogenesis","volume":"41","author":"Harrison","year":"2020","journal-title":"Trends Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.3201\/eid2807.220526","article-title":"SARS-CoV-2 Delta-Omicron Recombinant Viruses, United States","volume":"28","author":"Lacek","year":"2022","journal-title":"Emerg. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1002\/jmv.27526","article-title":"Omicron and Delta variant of SARS-CoV-2: A comparative computational study of spike protein","volume":"94","author":"Kumar","year":"2022","journal-title":"J. Med. Virol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Duong, B.V., Larpruenrudee, P., Fang, T., Hossain, S.I., Saha, S.C., Gu, Y., and Islam, M.S. (2022). Is the SARS CoV-2 Omicron Variant Deadlier and More Transmissible Than Delta Variant?. Int. J. Environ. Res. Public Health, 19.","DOI":"10.3390\/ijerph19084586"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1208\/s12249-021-02058-y","article-title":"Tozinameran (BNT162b2) Vaccine: The Journey from Preclinical Research to Clinical Trials and Authorization","volume":"22","author":"Khehra","year":"2021","journal-title":"AAPS PharmSciTech"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Patel, P., Macdonald, J.C., Boobalan, J., Marsden, M., Rizzi, R., Zenon, M., Ren, J., Chu, H., Cappelleri, J.C., and Roychoudhury, S. (2023). Regulatory agilities impacting review timelines for Pfizer\/BioNTech\u2019s BNT162b2 mRNA COVID-19 vaccine: A retrospective study. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1275817"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1038\/s41590-021-01021-0","article-title":"mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates","volume":"22","author":"Corbett","year":"2021","journal-title":"Nat. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1016\/j.vaccine.2023.03.076","article-title":"Factors associated with receipt of mRNA-1273 vaccine at a United States national retail pharmacy during the COVID-19 pandemic","volume":"41","author":"Buck","year":"2023","journal-title":"Vaccine"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S0140-6736(20)32623-4","article-title":"Oxford-AstraZeneca COVID-19 vaccine efficacy","volume":"397","author":"Knoll","year":"2021","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"S159","DOI":"10.1093\/cid\/ciac439","article-title":"Effectiveness of the Ad26.COV2.S (Johnson & Johnson) Coronavirus Disease 2019 (COVID-19) Vaccine for Preventing COVID-19 Hospitalizations and Progression to High Disease Severity in the United States","volume":"75","author":"Lewis","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1001\/jama.2021.3645","article-title":"Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19","volume":"325","author":"Stephenson","year":"2021","journal-title":"JAMA"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2096970","DOI":"10.1080\/21645515.2022.2096970","article-title":"CoronaVac: A review of efficacy, safety, and immunogenicity of the inactivated vaccine against SARS-CoV-2","volume":"18","author":"Jin","year":"2022","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1002\/jmv.27604","article-title":"Dynamics of antibody response to CoronaVac vaccine","volume":"94","author":"Fonseca","year":"2022","journal-title":"J. Med. Virol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Belayachi, J., Yang, Y., Fu, Q., Rodewald, L., Li, H., Yan, B., Wang, Y., Shen, Y., and Yang, Q. (2022). Real-world study of the effectiveness of BBIBP-CorV (Sinopharm) COVID-19 vaccine in the Kingdom of Morocco. BMC Public Health, 22.","DOI":"10.1186\/s12889-022-14016-9"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Abdelhafiz, A.S., Ali, A., Kamel, M.M., Ahmed, E.H., Sayed, D.M., and Bakry, R.M. (2022). Sinopharm\u2019s BBIBP-CorV Vaccine and ChAdOx1 nCoV-19 Vaccine Are Associated with a Comparable Immune Response against SARS-CoV-2. Vaccines, 10.","DOI":"10.3390\/vaccines10091462"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1586\/erv.10.115","article-title":"Virus-like particles in vaccine development","volume":"9","author":"Mellado","year":"2010","journal-title":"Expert. Rev. Vaccines"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"531","DOI":"10.18388\/abp.2014_1875","article-title":"Virus-like particles as vaccine","volume":"61","author":"Chroboczek","year":"2014","journal-title":"Acta Biochim. Pol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.coviro.2016.03.001","article-title":"Engineering virus-like particles as vaccine platforms","volume":"18","author":"Frietze","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"S343","DOI":"10.1093\/infdis\/jiaa668","article-title":"Hepatitis B Vaccines","volume":"224","author":"Pattyn","year":"2021","journal-title":"J. Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.smim.2017.08.014","article-title":"Major findings and recent advances in virus-like particle (VLP)-based vaccines","volume":"34","author":"Mohsen","year":"2017","journal-title":"Semin. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1080\/21645515.2017.1289301","article-title":"HPV vaccines: Global perspectives","volume":"13","author":"Gupta","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(23)02234-1","article-title":"Long-term efficacy of a recombinant hepatitis E vaccine in adults: 10-year results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"403","author":"Huang","year":"2024","journal-title":"Lancet"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/s41467-020-20654-7","article-title":"A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses","volume":"12","author":"Tan","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Chu, K.B., Kang, H.J., Yoon, K.W., Lee, H.A., Moon, E.K., Han, B.K., and Quan, F.S. (2021). Influenza Virus-like Particle (VLP) Vaccines Expressing the SARS-CoV-2 S Glycoprotein, S1, or S2 Domains. Vaccines, 9.","DOI":"10.3390\/vaccines9080920"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Yang, H., Tian, J., Zhao, J., Zhao, Y., and Zhang, G. (2024). The Application of Newcastle Disease Virus (NDV): Vaccine Vectors and Tumor Therapy. Viruses, 16.","DOI":"10.3390\/v16060886"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Fulber, J.P.C., and Kamen, A.A. (2022). Development and Scalable Production of Newcastle Disease Virus-Vectored Vaccines for Human and Veterinary Use. Viruses, 14.","DOI":"10.3390\/v14050975"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4513","DOI":"10.1128\/JVI.01931-09","article-title":"Assembly and biological and immunological properties of Newcastle disease virus-like particles","volume":"84","author":"McGinnes","year":"2010","journal-title":"J. Virol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"11062","DOI":"10.1128\/JVI.00726-06","article-title":"Requirements for the assembly and release of Newcastle disease virus-like particles","volume":"80","author":"Pantua","year":"2006","journal-title":"J. Virol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"545","DOI":"10.2217\/fvl.10.50","article-title":"Newcastle disease virus-like particles as a platform for the development of vaccines for human and agricultural pathogens","volume":"5","author":"Morrison","year":"2010","journal-title":"Future Virol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Yang, Y., Shi, W., Abiona, O.M., Nazzari, A., Olia, A.S., Ou, L., Phung, E., Stephens, T., Tsybovsky, Y., and Verardi, R. (2021). Newcastle Disease Virus-Like Particles Displaying Prefusion-Stabilized SARS-CoV-2 Spikes Elicit Potent Neutralizing Responses. Vaccines, 9.","DOI":"10.3390\/vaccines9020073"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1126\/science.abe1502","article-title":"Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate","volume":"370","author":"Bangaru","year":"2020","journal-title":"Science"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Hu, J., Zhang, Q., Peng, P., Li, R., Li, J., Wang, X., Gu, M., Hu, Z., Hu, S., and Liu, X. (2022). Baculovirus-derived influenza virus-like particle confers complete protection against lethal H7N9 avian influenza virus challenge in chickens and mice. Vet. Microbiol., 264.","DOI":"10.1016\/j.vetmic.2021.109306"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Li, J., Li, R., Zhang, Q., Peng, P., Wang, X., Gu, M., Hu, Z., Jiao, X., Peng, D., and Hu, J. (2021). H7N9 influenza virus-like particle based on BEVS protects chickens from lethal challenge with highly pathogenic H7N9 avian influenza virus. Vet. Microbiol., 258.","DOI":"10.1016\/j.vetmic.2021.109106"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/oxfordjournals.aje.a118408","article-title":"A simple method of estimating fifty per cent endpoints","volume":"27","author":"Reed","year":"1938","journal-title":"Am. J. Epidemiol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Wei, J., Alfajaro, M.M., Cai, W.L., Graziano, V.R., Strine, M.S., Filler, R.B., Biering, S.B., Sarnik, S.A., Patel, S., and Menasche, B.L. (2023). The KDM6A-KMT2D-p300 axis regulates susceptibility to diverse coronaviruses by mediating viral receptor expression. PLoS Pathog., 19.","DOI":"10.1371\/journal.ppat.1011351"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1084\/jem.20051639","article-title":"Antigen targeting to dendritic cells elicits long-lived T cell help for antibody responses","volume":"203","author":"Boscardin","year":"2006","journal-title":"J. Exp. Med."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Cui, X., Xiang, Q., Huang, Y., Ji, Q., Hu, Z., Shi, T., Bao, G., and Liu, Y. (2024). Mixed Th1\/Th2\/Th17 Responses Induced by Plant Oil Adjuvant-Based B. bronchiseptica Vaccine in Mice, with Mechanisms Unraveled by RNA-Seq, 16S rRNA and Metabolomics. Vaccines, 12.","DOI":"10.3390\/vaccines12101182"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/35038103","article-title":"Development of Th1-type immune responses requires the type I cytokine receptor TCCR","volume":"407","author":"Chen","year":"2000","journal-title":"Nature"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.4049\/jimmunol.172.4.2059","article-title":"IL-4 induces differentiation and expansion of Th2 cytokine-producing eosinophils","volume":"172","author":"Chen","year":"2004","journal-title":"J. Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e28237","DOI":"10.1002\/jmv.28237","article-title":"Development of SARS-CoV-2 animal vaccines using a stable and efficient NDV expression system","volume":"95","author":"He","year":"2023","journal-title":"J. Med. Virol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41541-024-00870-8","article-title":"Intranasal vaccination with an NDV-vectored SARS-CoV-2 vaccine protects against Delta and Omicron challenges","volume":"9","author":"Warner","year":"2024","journal-title":"NPJ Vaccines"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"105757","DOI":"10.1016\/j.antiviral.2023.105757","article-title":"Newcastle Disease Virus (NDV)-based vaccine candidate against SARS-CoV-2 Omicron by intranasal immunization","volume":"220","author":"Zhang","year":"2023","journal-title":"Antivir. Res."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Sun, W., McCroskery, S., Liu, W.C., Leist, S.R., Liu, Y., Albrecht, R.A., Slamanig, S., Oliva, J., Amanat, F., and Sch\u00e4fer, A. (2020). A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine. Vaccines, 8.","DOI":"10.1101\/2020.07.30.229120"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Shirvani, E., and Samal, S.K. (2020). Newcastle Disease Virus as a Vaccine Vector for SARS-CoV-2. Pathogens, 9.","DOI":"10.3390\/pathogens9080619"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1016\/j.cell.2022.05.022","article-title":"Humoral and cellular immune memory to four COVID-19 vaccines","volume":"185","author":"Zhang","year":"2022","journal-title":"Cell"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41541-022-00455-3","article-title":"Calibrated comparison of SARS-CoV-2 neutralizing antibody levels in response to protein-, mRNA-, and vector-based COVID-19 vaccines","volume":"7","author":"Karbiener","year":"2022","journal-title":"NPJ Vaccines"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Paramithiotis, E., Sugden, S., Papp, E., Bonhomme, M., Chermak, T., Crawford, S.Y., Demetriades, S.Z., Galdos, G., Lambert, B.L., and Mattison, J. (2022). Cellular Immunity Is Critical for Assessing COVID-19 Vaccine Effectiveness in Immunocompromised Individuals. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.880784"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"L\u00f8ken, R., and Fevang, B. (2023). Cellular immunity in COVID-19 and other infections in Common variable immunodeficiency. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1124279"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s41541-022-00561-2","article-title":"Safety and immunogenicity of an AS03-adjuvanted plant-based SARS-CoV-2 vaccine in Adults with and without Comorbidities","volume":"7","author":"Charland","year":"2022","journal-title":"NPJ Vaccines"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/12\/1932\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:54:22Z","timestamp":1760115262000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/12\/1932"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,18]]},"references-count":54,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["v16121932"],"URL":"https:\/\/doi.org\/10.3390\/v16121932","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,18]]}}}